Containment Contamination Contract Manufacturing Pharma Companies 
Pharmaceutical Technology
DECEMBER 6, 2022
Manufacturing these highly potent and often cytotoxic drugs introduces many risks for operators and the environment. Cross-contamination of standard products with highly potent ones is another key concern. Many companies are now prioritising investments in containment systems, GlobalData research shows.
Pharmaceutical Technology
JUNE 14, 2023
This, coupled with small pharma companies being unable to acquire or access containment capabilities in-house, means that the demand for innovative specialized small molecule capabilities remains high. Of those, only 935 (34%) small molecule API facilities offered some type of containment capabilities.
Expert insights. Personalized for you.
130 
Let's personalize your content